CSL Ltd. (CMXHF)
116.40
+0.96
(+0.83%)
USD |
OTCM |
Dec 10, 15:57
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 56.45B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -32.23% |
| Valuation | |
| PE Ratio | 18.85 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.668 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 54.79% |
Profile
| CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia. |
| URL | http://www.csl.com.au |
| Investor Relations URL | https://investors.csl.com/ |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 10, 2026 (est.) |
| Last Earnings Release | Aug. 18, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 13, 2019 |
Ratings
Profile
| CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia. |
| URL | http://www.csl.com.au |
| Investor Relations URL | https://investors.csl.com/ |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 10, 2026 (est.) |
| Last Earnings Release | Aug. 18, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 13, 2019 |